Base de dados : MEDLINE
Pesquisa : I01.409.418.750.600.650.496.150 [Categoria DeCS]
Referências encontradas : 949 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 95 ir para página                         

  1 / 949 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463161
[Au] Autor:Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
[Ad] Endereço:Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. Electronic address: ebasch@med.unc.edu.
[Ti] Título:Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):409-418, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). METHODS AND MATERIALS: Patients enrolled in NRG Oncology's RTOG 1012 (Prophylactic Manuka Honey for Reduction of Chemoradiation Induced Esophagitis-Related Pain during Treatment of Lung Cancer) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly ×4 during treatment; 12 weeks after treatment). Reporting was conducted via wireless tablet computers in clinic waiting areas. Compliance was defined as the proportion of visits when an expected PRO-CTCAE assessment was completed. RESULTS: Among 226 study sites participating in RTOG 1012, 100% completed 35-minute PRO-CTCAE training for clinical research associates (CRAs); 80 sites enrolled patients, of which 34 (43%) required tablet computers to be provided. All 152 patients in RTOG 1012 agreed to self-report using the PRO-CTCAE (median age 66 years; 47% female; 84% white). Median time for CRAs to learn the system was 60 minutes (range, 30-240 minutes), and median time for CRAs to teach a patient to self-report was 10 minutes (range, 2-60 minutes). Compliance was high, particularly during active treatment, when patients self-reported at 86% of expected time points, although compliance was lower after treatment (72%). Common reasons for noncompliance were institutional errors, such as forgetting to provide computers to participants; patients missing clinic visits; Internet connectivity; and patients feeling "too sick." CONCLUSIONS: Most patients enrolled in a multicenter chemoradiotherapy trial were willing and able to self-report symptomatic AEs at visits using tablet computers. Minimal effort was required by local site staff to support this system. The observed causes of missing data may be obviated by allowing patients to self-report electronically between visits, and by using central compliance monitoring. These approaches are being incorporated into ongoing studies.
[Mh] Termos MeSH primário: Quimiorradioterapia/efeitos adversos
Esofagite/complicações
Neoplasias Pulmonares/terapia
Microcomputadores/estatística & dados numéricos
Dor/prevenção & controle
Cooperação do Paciente/estatística & dados numéricos
Medidas de Resultados Relatados pelo Paciente
Autorrelato/utilização
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Apiterapia/métodos
Transtornos de Deglutição/etiologia
Transtornos de Deglutição/terapia
Estudos de Viabilidade
Feminino
Mel
Seres Humanos
Internet
Masculino
Meia-Idade
National Cancer Institute (U.S.)
Avaliação de Sintomas/estatística & dados numéricos
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  2 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463152
[Au] Autor:Yang DD; Muralidhar V; Mahal BA; Labe SA; Nezolosky MD; Vastola ME; King MT; Martin NE; Orio PF; Choueiri TK; Trinh QD; Spratt DE; Hoffman KE; Feng FY; Nguyen PL
[Ad] Endereço:Harvard Medical School, Boston, Massachusetts.
[Ti] Título:National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):338-343, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Androgen deprivation therapy (ADT) is not recommended for low-risk prostate cancer because of its lack of benefit and potential for harm. We evaluated the incidence and predictors of ADT use in low-risk disease. METHODS AND MATERIALS: Using the National Cancer Database, we identified 197,957 patients with low-risk prostate cancer (Gleason score of 3 + 3 = 6, prostate-specific antigen level <10 ng/mL, and cT1-T2a) diagnosed from 2004 to 2012 with complete demographic and treatment information. We used multiple logistic regression to evaluate predictors of ADT use and Cox regression to examine its association with all-cause mortality. RESULTS: Overall ADT use decreased from 17.6% in 2004 to 3.5% in 2012. In 2012, 11.5% of low-risk brachytherapy patients and 7.6% of external beam radiation therapy patients received ADT. Among 82,352 irradiation-managed patients, predictors of ADT use included treatment in a community versus academic cancer program (adjusted odds ratio [AOR], 1.60; 95% confidence interval [CI], 1.50-1.71; P<.001; incidence, 14.0% vs 6.0% in 2012); treatment in the South (AOR, 1.51), Midwest (AOR, 1.81), or Northeast (AOR, 1.90) versus West (P<.001); and brachytherapy use versus external beam radiation therapy (AOR, 1.32; 95% CI, 1.27-1.37; P<.001). Among 25,196 patients who did not receive local therapy, predictors of primary ADT use included a Charlson-Deyo comorbidity score of ≥2 versus 0 (AOR, 1.42; 95% CI, 1.06-1.91; P=.018); treatment in a community versus academic cancer program (AOR, 1.61; 95% CI, 1.37-1.90; P<.001); and treatment in the South (AOR, 1.26), Midwest (AOR, 1.52), or Northeast (AOR, 1.28) versus West (P≤.008). Primary ADT use was associated with increased all-cause mortality in patients who did not receive local therapy (adjusted hazard ratio, 1.28; 95% CI, 1.14-1.43; P<.001) after adjustment for age and comorbidity. CONCLUSIONS: ADT use in low-risk prostate cancer has declined nationally but may remain an issue of concern in certain populations and regions.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Centros Médicos Acadêmicos/estatística & dados numéricos
Centros Médicos Acadêmicos/tendências
Adulto
Idoso
Idoso de 80 Anos ou mais
Braquiterapia/utilização
Institutos de Câncer/estatística & dados numéricos
Institutos de Câncer/tendências
Centros Comunitários de Saúde/estatística & dados numéricos
Centros Comunitários de Saúde/tendências
Crioterapia/utilização
Bases de Dados Factuais/estatística & dados numéricos
Seres Humanos
Modelos Logísticos
Masculino
Meia-Idade
National Cancer Institute (U.S.)/estatística & dados numéricos
Gradação de Tumores
Modelos de Riscos Proporcionais
Prostatectomia/utilização
Neoplasias da Próstata/epidemiologia
Neoplasias da Próstata/radioterapia
Neoplasias da Próstata/cirurgia
Radioterapia/utilização
Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androgen Antagonists)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  3 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29208398
[Au] Autor:Jaffee EM; Dang CV; Agus DB; Alexander BM; Anderson KC; Ashworth A; Barker AD; Bastani R; Bhatia S; Bluestone JA; Brawley O; Butte AJ; Coit DG; Davidson NE; Davis M; DePinho RA; Diasio RB; Draetta G; Frazier AL; Futreal A; Gambhir SS; Ganz PA; Garraway L; Gerson S; Gupta S; Heath J; Hoffman RI; Hudis C; Hughes-Halbert C; Ibrahim R; Jadvar H; Kavanagh B; Kittles R; Le QT; Lippman SM; Mankoff D; Mardis ER; Mayer DK; McMasters K; Meropol NJ; Mitchell B; Naredi P; Ornish D; Pawlik TM; Peppercorn J; Pomper MG; Raghavan D; Ritchie C; Schwarz SW; Sullivan R
[Ad] Endereço:The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: ejaffee@jhmi.edu.
[Ti] Título:Future cancer research priorities in the USA: a Lancet Oncology Commission.
[So] Source:Lancet Oncol;18(11):e653-e706, 2017 Nov.
[Is] ISSN:1474-5488
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.
[Mh] Termos MeSH primário: Pesquisa Biomédica/tendências
Planejamento em Saúde/tendências
Prioridades em Saúde
National Cancer Institute (U.S.)/tendências
Neoplasias/terapia
[Mh] Termos MeSH secundário: Pesquisa Biomédica/métodos
Previsões
Seres Humanos
Oncologia/tendências
Neoplasias/diagnóstico
Medicina de Precisão/tendências
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  4 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28956723
[Au] Autor:Strekalova YA; Krieger JL
[Ad] Endereço:a College of Journalism and Communications , University of Florida , Gainesville , Florida , USA.
[Ti] Título:Beyond Words: Amplification of Cancer Risk Communication on Social Media.
[So] Source:J Health Commun;22(10):849-857, 2017 Oct.
[Is] ISSN:1087-0415
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Social media provide a unique channel for disseminating evidence-based information to diverse audiences and organizational and private stakeholders, thus facilitating a dialog about health and health risks. Guided by the social amplification of risk framework, the goal of this study was to assess the level of audience engagement with messages posted on the National Cancer Institute (NCI) Facebook page and evaluate the differences in the audience information behavior toward risk-related and non-risk posts. Data included 1,975 posts published on the NCI Facebook page as well as the corresponding 4,537 comments, 77,298 shares, and 145,462 likes. Links and images were the top two most frequent types of content for both risk-related and non-risk posts, but risk-related messages were more amplified through comments, shares, and likes. Comparing the modality of risk-related messages, videos, contrary to the prediction, were not more effective in attracting audience engagement than images. Finally, comments to risk-related posts did not repeat risk-related language suggesting that future studies should examine risk signal recognition and dissemination as separate behaviors. This study's findings emphasize the importance of focused investigation of message design strategies and message effects on the dissemination and amplification of communication related to health risks.
[Mh] Termos MeSH primário: Comunicação em Saúde
National Cancer Institute (U.S.)
Neoplasias
Mídias Sociais/estatística & dados numéricos
[Mh] Termos MeSH secundário: Seres Humanos
Risco
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1080/10810730.2017.1367336


  5 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28927536
[Au] Autor:Zeiger E
[Ad] Endereço:Errol Zeiger Consulting, 800 Indian Springs Road., Chapel Hill, NC 27514, USA. Electronic address: zeiger@nc.rr.com.
[Ti] Título:Reflections on a career and on the history of genetic toxicity testing in the National Toxicology Program.
[So] Source:Mutat Res;773:282-292, 2017 Jul.
[Is] ISSN:1873-135X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:One of the highly visible aspects of the U.S. National Toxicology Program (NTP) has been its genetic toxicity testing program, which has been responsible for testing, and making publicly available, in vitro and in vivo test data on thousands of chemicals since 1979. What is less well known, however, is that this NTP program had its origin in two separate testing programs that were initiated independently at the National Cancer Institute (NCI) and the National Institute of Environmental Health Sciences (NIEHS) before the NTP was established. The NCI program was in response to the 1971 National Cancer Act which dramatically increased the NCI budget. In contrast, the NIEHS testing program can be traced back to a publication by Bruce Ames, not the one describing the mutagenicity assay he developed that became known as the Ames test, but because in 1975 he published an article showing that hair dyes were mutagenic. The protocols developed for these NCI contracts became the basis for the NTP Salmonella testing contracts that were awarded a few years later. These protocols, with their supporting NTP data, strongly influenced the initial in vitro OECD Test Guidelines. The background and evolution of the NTP genetic toxicity testing program is described, along with some of the more significant milestone discoveries and accomplishments from this program.
[Mh] Termos MeSH primário: Testes de Mutagenicidade
United States Government Agencies/história
[Mh] Termos MeSH secundário: Animais
Bioensaio
Linhagem Celular
Bases de Dados Factuais
História do Século XX
História do Século XXI
Seres Humanos
Camundongos
Mutagênicos/toxicidade
National Cancer Institute (U.S.)
National Institute of Environmental Health Sciences (U.S.)
Salmonella typhimurium/efeitos dos fármacos
Estados Unidos
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Mutagens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170921
[St] Status:MEDLINE


  6 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28888324
[Au] Autor:Varmus H
[Ad] Endereço:Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA. Electronic address: varmus@med.cornell.edu.
[Ti] Título:A Prize for Cancer Prevention.
[So] Source:Cell;171(1):14-17, 2017 Sep 21.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This year's Lasker-DeBakey Prize for Clinical Research to Douglas Lowy and John Schiller celebrates the science behind one of the greatest advances in the history of cancer research: the development of vaccines that prevent infection and thus prevent tumor induction by pathogenic strains of human papilloma virus (HPV).
[Mh] Termos MeSH primário: Distinções e Prêmios
Papillomavirus Humano 16/fisiologia
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/imunologia
Neoplasias do Colo do Útero/prevenção & controle
[Mh] Termos MeSH secundário: Feminino
História do Século XX
História do Século XXI
Seres Humanos
Masculino
National Cancer Institute (U.S.)
Infecções por Papillomavirus/imunologia
Infecções por Papillomavirus/virologia
Vacinas contra Papillomavirus/história
Estados Unidos
Neoplasias do Colo do Útero/imunologia
Neoplasias do Colo do Útero/virologia
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Ps] Nome de pessoa como assunto:Lowy D; Schiller J
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170911
[St] Status:MEDLINE


  7 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28888323
[Ti] Título:Two Basic Scientists Walk into a Translational Space.
[So] Source:Cell;171(1):23-27, 2017 Sep 21.
[Is] ISSN:1097-4172
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:When John Schiller first joined Douglas Lowy's lab at the National Cancer Institute of the NIH, he could have not predicted that their common interest in the molecular biology of oncogenes would set them in path for discoveries that ultimately enabled the development of a vaccine for the human papillomavirus, which causes the majority of cervical cancers worldwide. John and Doug, the recipients of the 2017 Lasker-DeBakey Clinical Award, have joined Cell editor João Monteiro in a Conversation about science, public health, and the joys and challenges of being basic scientists in a translational space. Annotated excerpts from this conversation are presented below.
[Mh] Termos MeSH primário: Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Feminino
História do Século XX
História do Século XXI
Seres Humanos
Masculino
National Cancer Institute (U.S.)
Papillomaviridae
Vacinas contra Papillomavirus/história
Estados Unidos
Neoplasias do Colo do Útero/prevenção & controle
Neoplasias do Colo do Útero/virologia
[Pt] Tipo de publicação:HISTORICAL ARTICLE; INTERVIEW
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170911
[St] Status:MEDLINE


  8 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28885797
[Au] Autor:Hopewood P
[Ti] Título:Using the NCDB to explore trends in cancer.
[So] Source:Bull Am Coll Surg;102(7):78-80, 2017 07.
[Is] ISSN:0002-8045
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Bases de Dados Factuais/estatística & dados numéricos
Neoplasias/epidemiologia
Sistema de Registros/estatística & dados numéricos
[Mh] Termos MeSH secundário: Centers for Disease Control and Prevention (U.S.)
Seres Humanos
National Cancer Institute (U.S.)
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:H
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE


  9 / 949 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28738442
[Au] Autor:Polite BN; Adams-Campbell LL; Brawley OW; Bickell N; Carethers JM; Flowers CR; Foti M; Gomez SL; Griggs JJ; Lathan CS; Li CI; Lichtenfeld JL; McCaskill-Stevens W; Paskett ED
[Ad] Endereço:Associate Professor of Medicine, Department of Medicine, The University of Chicago, Chicago, IL.
[Ti] Título:Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.
[So] Source:CA Cancer J Clin;67(5):353-361, 2017 09.
[Is] ISSN:1542-4863
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: American Cancer Society
Disparidades em Assistência à Saúde/estatística & dados numéricos
Oncologia
National Cancer Institute (U.S.)
Neoplasias/prevenção & controle
[Mh] Termos MeSH secundário: Afroamericanos/estatística & dados numéricos
Pesquisa Biomédica/tendências
Ensaios Clínicos como Assunto
Grupo com Ancestrais do Continente Europeu/estatística & dados numéricos
Disparidades em Assistência à Saúde/tendências
Seres Humanos
Incidência
Medicaid
Grupos Minoritários/estatística & dados numéricos
National Cancer Institute (U.S.)/tendências
Neoplasias/diagnóstico
Neoplasias/etnologia
Patient Protection and Affordable Care Act/tendências
Fatores de Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:GUIDELINE; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170725
[St] Status:MEDLINE
[do] DOI:10.3322/caac.21404


  10 / 949 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28721913
[Au] Autor:Kim KY; Le QT; Yom SS; Ng RHW; Chan KCA; Bratman SV; Welch JJ; Divi RL; Petryshyn RA; Conley BA
[Ad] Endereço:Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: kimke@mail.nih.gov.
[Ti] Título:Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.
[So] Source:Int J Radiat Oncol Biol Phys;98(5):996-1001, 2017 Aug 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Epstein-Barr virus (EBV) DNA analysis has been shown to be useful for early detection, prognostication, and monitoring of treatment response of nasopharyngeal carcinoma (NPC), and the recent literature provides growing evidence of the clinical utility of EBV DNA testing, particularly to inform treatment decisions for NPC patients. Despite the fact that NPC is a rare disease, the NRG Oncology cooperative group has successfully activated a phase 2/3 randomized clinical trial for NPC with international partners and in that process has discovered that the development of a harmonized EBV DNA test is absolutely critical for integration into clinical trials and for future deployment in clinical and central laboratories. In November 2015, the National Cancer Institute (NCI) convened a workshop of international experts in the treatment of NPC and EBV testing to provide a forum for discussing the state of EBV DNA testing and its clinical utility, and to stimulate consideration of future studies and clinical practice guidelines for EBV DNA. This review provides a summary of that discussion.
[Mh] Termos MeSH primário: Carcinoma/terapia
Carcinoma/virologia
DNA Viral/sangue
Herpesvirus Humano 4/genética
Neoplasias Nasofaríngeas/terapia
Neoplasias Nasofaríngeas/virologia
[Mh] Termos MeSH secundário: Biomarcadores Tumorais/sangue
Carcinoma/diagnóstico
Carcinoma/mortalidade
Quimiorradioterapia
Quimioterapia Adjuvante
Detecção Precoce de Câncer
Marcadores Genéticos
Seres Humanos
Neoplasias Nasofaríngeas/diagnóstico
Neoplasias Nasofaríngeas/mortalidade
National Cancer Institute (U.S.)
Recidiva Local de Neoplasia/sangue
Recidiva Local de Neoplasia/virologia
Estadiamento de Neoplasias
Prognóstico
Ensaios Clínicos Controlados Aleatórios como Assunto
Estados Unidos
[Pt] Tipo de publicação:CONSENSUS DEVELOPMENT CONFERENCE, NIH; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (DNA, Viral); 0 (Genetic Markers)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE



página 1 de 95 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde